1. Home
  2. LITB vs RNTX Comparison

LITB vs RNTX Comparison

Compare LITB & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LITB

LightInTheBox Holding Co. Ltd.

N/A

Current Price

$3.23

Market Cap

57.1M

ML Signal

N/A

Logo Rein Therapeutics Inc.

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$0.74

Market Cap

65.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LITB
RNTX
Founded
2007
2001
Country
Singapore
United States
Employees
N/A
10
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
57.1M
65.7M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
LITB
RNTX
Price
$3.23
$0.74
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
3.8K
385.3K
Earning Date
05-12-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$14.50
N/A
Revenue Next Year
$11.59
N/A
P/E Ratio
$10.96
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.15
$0.73
52 Week High
$4.17
$2.18

Technical Indicators

Market Signals
Indicator
LITB
RNTX
Relative Strength Index (RSI) 47.15 33.10
Support Level $2.81 N/A
Resistance Level $3.36 $1.32
Average True Range (ATR) 0.22 0.08
MACD -0.03 -0.01
Stochastic Oscillator 35.00 8.95

Price Performance

Historical Comparison
LITB
RNTX

About LITB LightInTheBox Holding Co. Ltd.

LightInTheBox Holding Co Ltd is a e-commerce company, providing a diverse range of affordable lifestyle products directly to consumers. Its brands include Ador, a women's fashion brand targeting women aged 35-55; the second is a golf apparel brand focusing on female golfers aged 35 and above; the third is a women's light party dress brand for the age group of 30 and above. It offers customers products through websites and mobile applications. The company operates and reviews its performance in two segments: Product sales which consisted of online retailing of consumer products and sales to third-party sellers, and Services which consisted of the provision of logistic services to companies and individual customers.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: